Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention
Panel to feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies
Download this press release (284 KB).
ROSEVILLE, MN – JUNE 01, 2018 — Rebiotix Inc., announced today that co-founder, president and CEO, Lee Jones, will be among the participants during a microbiome-focused panel discussion at the 2018 BIO International Convention meeting in Boston, June 1-7. The panel, titled “The Path from Bugs to Drugs: Approaches to Microbiome-Based Therapies,” will explore topics highlighting microbiome therapeutics and where the greatest promise to deliver evidence-based clinical outcomes will be in the future.
Joining Ms. Jones on the panel will be several leaders in the field of microbiome development, investment and commercialization, including Dr. Mervyn Turner, Ph.D., CEO of MJ Turner Consulting and former Chief Strategy Officer of Merck & Co Inc, and Per Falk, MD, Ph.D., Chief Science Officer at Ferring Pharmaceuticals. On April 5, Ferring and Rebiotix announced the acquisition of Rebiotix by Ferring.
“As the leader in the microbiome therapeutics industry, Rebiotix values opportunities to participate in discussions that fuel innovation and help to pave the way for the first microbiome-derived products to advance from bench to bedside,” said Ms. Jones. “The 2018 BIO International Convention is an ideal venue for such a discussion, and I look forward to joining the other panelists as we explore the opportunities of microbiome drug development and the promising future for microbiome-based therapies.”
Details of the microbiome panel discussion are as follows: